Unmet needs in the management of psoriasis in Latin America: a systematic review

Ossanai Schoenardie, Bruna; Oliveira Almeida, Rodrigo; Hanemann, Thaísa; Ossanai Schoenardie, Arthur; Ribeiro, André Lucas; Catucci Boza, Juliana

doi:10.1016/j.abd.2023.04.006

Cited by 2 publications

(1 citation statement)

References 58 publications

(98 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VOYAGE I included three subject groups: those who received only guselkumab 100 mg; a group who received placebo at weeks zero, four, and 12 followed by guselkumab 100 mg through week 44; and those who received only adalimumab 80 mg. VOYAGE II included similar subject groups, but the study also included a crossover design. In this design, guselkumab responders with a PASI score of 90 at week 28 were randomized to receive guselkumab (maintenance group) or placebo followed by guselkumab after a loss of response (withdrawal group) [44]. The crossover study design offered many benefits: it confirmed the efficacy of data from VOYAGE I, allowed subjects to serve as their own corresponding controls, and lastly, simulated non-continuous treatment of the drug, a frequent occurrence in real clinical practice.…”

Section: Guselkumab Use In Plaque Psoriasismentioning

confidence: 99%

Guselkumab, a Novel Monoclonal Antibody Inhibitor of the p19 Subunit of IL-23, for Psoriatic Arthritis and Plaque Psoriasis: A Review of Its Mechanism, Use, and Clinical Effectiveness

Kerut,

Wagner,

Daniel

et al. 2023

Cureus

View full text Add to dashboard Cite

Psoriatic arthritis and plaque psoriasis are autoimmune conditions affecting multiple organs, including the skin. The pathophysiology and etiology of these conditions are not fully understood; however, numerous factors are believed to play a critical role, including genetics and environmental risk factors. Furthermore, research suggests the IL-23/IL-17 pathway partially mediates these diseases. Once the IL-23 receptor is bound and activated, two subunits, p19, and p40, act through different signaling pathways. Ultimately, inflammation is produced through the effector molecule, IL-17, other cytokines, and tumor necrosis factor (TNF). Traditionally, these chronic conditions have been treated with TNF-α inhibitors and methotrexate, a dihydrofolate reductase inhibitor. Although successful in inhibiting the immune system, these drugs can have many adverse effects due to their broad targets. In recent years, more targeted therapy has become popular. Guselkumab is a monoclonal antibody that inhibits the p19 subunit of IL-23. It has been FDA-approved to treat both plaque psoriasis and psoriatic arthritis. Clinical trials showing guselkumab’s efficacy have been promising, even showing improvement in symptoms of plaque psoriasis patients resistant to adalimumab, a TNF-α inhibitor. Guselkumab has also been shown to be well tolerated with a similar safety profile as other biologics inhibiting the immune system. In addition to its efficacy in treating plaque psoriasis and psoriatic arthritis, the mechanism of action offers a targeted approach that may minimize the broad immunosuppressive effects often associated with traditional therapies, providing a potential advantage in the long-term management of these autoimmune conditions.

show abstract

Section: Guselkumab Use In Plaque Psoriasismentioning

confidence: 99%

Guselkumab, a Novel Monoclonal Antibody Inhibitor of the p19 Subunit of IL-23, for Psoriatic Arthritis and Plaque Psoriasis: A Review of Its Mechanism, Use, and Clinical Effectiveness

Kerut,

Wagner,

Daniel

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

Experience of living with psoriasis in Brazil: a Global Psoriasis Atlas online survey

Silva,

Wright,

Carvalho

et al. 2024

Int J Dermatology

View full text Add to dashboard Cite

BackgroundPsoriasis significantly burdens patients' lives, but there is limited data on this in Brazil.MethodsBetween May 2022 and January 2023, we conducted a cross‐sectional online survey of 563 Brazilian residents aged ≥18 years who had been diagnosed with psoriasis. Spearman's correlation (r) was used to test the correlation between self‐assessed disease severity (Simplified Psoriasis Index [saSPI] extent score; range 0 [clear/minor] to 40 [widespread/severe]) and health‐related quality of life (QoL, score of 1 means perfect health) and capability (ICECAP‐A: score of 1 means full capability) measures. Multivariable linear regression was used to identify predictors of QoL and capability. A thematic analysis examined the free‐text responses and identified common themes.ResultsThe mean age of participants was 42.1 ± 12.4 years, and over half had at least one other long‐term condition. The mean QoL score was 0.59 ± 0.25, and the mean capability score was 0.71 ± 0.21. At the time of survey completion, over 80% of respondents reported some level of pain and/or discomfort, and 86% reported feeling anxious and/or depressed. The mean self‐assessed saSPI was 7.8 ± 8.6, which negatively correlated with health‐related QoL (r = −0.49, P < 0.05) and capability (r = −0.44, P < 0.05). Significant predictors of poorer QoL and reduced capability included high saSPI, number of psoriasis flares and comorbidities, female gender, Black ethnicity, and employment status (unemployed, long‐term sick). Frequently reported areas that impacted patients were social stigma/prejudice, powerlessness, lack of education and public awareness, and difficulty obtaining appropriate care/treatment.ConclusionsWe found that the clinical manifestations, severity, and associated comorbidities of psoriasis negatively impacted health‐related QoL and capability, along with feelings of stigmatization and barriers to specialist treatment. This highlights the need for better access to care and awareness of the disease to improve the lives of people living with psoriasis in Brazil.

show abstract

Unmet needs in the management of psoriasis in Latin America: a systematic review

Cited by 2 publications

References 58 publications

Guselkumab, a Novel Monoclonal Antibody Inhibitor of the p19 Subunit of IL-23, for Psoriatic Arthritis and Plaque Psoriasis: A Review of Its Mechanism, Use, and Clinical Effectiveness

Guselkumab, a Novel Monoclonal Antibody Inhibitor of the p19 Subunit of IL-23, for Psoriatic Arthritis and Plaque Psoriasis: A Review of Its Mechanism, Use, and Clinical Effectiveness

Experience of living with psoriasis in Brazil: a Global Psoriasis Atlas online survey

Contact Info

Product

Resources

About